- In February 2025, Lion TCR received clearance from the U.S. Food and Drug Administration (FDA) to initiate an international multicenter Phase 2 clinical trial for its mRNA-encoded T-cell receptor (TCR)-T cell therapy product, Liocyx-M004. This regulatory milestone not only reinforces Lion TCR’s leadership in the mRNA-based TCR-T cell therapy space but also marks a significant advancement in the hepatocellular carcinoma (HCC) drugs market
- In October 2022, the U.S. Food and Drug Administration approved tremelimumab (Imjudo) in combination with durvalumab, both from AstraZeneca Pharmaceuticals, for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC). This approval marked a key milestone in the HCC drugs market, expanding the range of immunotherapy-based treatment options available for advanced-stage patients
